Compare NPCE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | ENTA |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.6M | 486.3M |
| IPO Year | 2021 | 2012 |
| Metric | NPCE | ENTA |
|---|---|---|
| Price | $14.19 | $12.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $18.33 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 206.8K | 174.6K |
| Earning Date | 05-25-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.03 | ★ 29.93 |
| EPS | N/A | ★ N/A |
| Revenue | $99,986,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $0.93 | $5.91 |
| Revenue Next Year | $25.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.13 | 16.48 |
| 52 Week Low | $7.56 | $4.09 |
| 52 Week High | $18.97 | $17.15 |
| Indicator | NPCE | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 40.69 |
| Support Level | $12.47 | $12.09 |
| Resistance Level | $16.96 | $15.52 |
| Average True Range (ATR) | 0.83 | 0.74 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 53.80 | 9.78 |
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.